Quarterly Result12 Feb 2026, 07:37 pm
Welcure Drugs & Pharmaceuticals Ltd. Approves Unaudited Financial Results for Q3 2025
AI Summary
The Board of Directors of Welcure Drugs & Pharmaceuticals Ltd. met on 12th February, 2026, and approved the unaudited financial results for the quarter ended 31st December, 2025. The results were reviewed by Sarang Shivajirao Chavan & Associates, the independent auditor, in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's management is responsible for the preparation of the financial statements in accordance with Ind AS 34 and other accounting principles generally accepted in India.
Key Highlights
- Welcure Drugs & Pharmaceuticals Ltd. approved the unaudited financial results for Q3 2025.
- The results were reviewed by Sarang Shivajirao Chavan & Associates, the independent auditor.
- The financial statements were prepared in accordance with Ind AS 34 and other accounting principles generally accepted in India.
- The company was advised to take external confirmation via email from each concerned party for debtors, creditors, investments, deposits, loans, and advances.
- The independent auditor did not express an opinion on the statement due to insufficient and inappropriate audit evidence.
Price Impact
More from WELCURE